Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2024

In 2024, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 31.61% of shares outstanding on 12 Jan 2024 to 34.57% on 31 Dec 2024, a change of +2.96 percentage points. The year's high was 39.66% on 31 Jul 2024 and its low 25.93% on 31 May 2024, averaging 32.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.29 days on 28 Mar 2024. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2024

2024 in figures

Start of year
31.61% (12 Jan 2024)
End of year
34.57% (31 Dec 2024)
Change
+2.96 pp
High
39.66% (31 Jul 2024)
Low
25.93% (31 May 2024)
Average
32.22%
Highest days to cover
25.29 (28 Mar 2024)
SEC filings marked
8

Every report in 2024

FILANA THERAPEUTICS, INC. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202431.61%13.32
31 Jan 202428.89%18.22
15 Feb 202427.89%23.47
29 Feb 202426.18%22.2310-K filed, results (8-K)
15 Mar 202427.67%13.41
28 Mar 202427.27%25.29
15 Apr 202429.71%11.03
30 Apr 202432.08%16.17
15 May 202426.68%13.2410-Q filed, results (8-K)
31 May 202425.93%25.16
14 Jun 202426.36%17.77
28 Jun 202427.29%5.19
15 Jul 202433.63%4.75
31 Jul 202439.66%3.63
15 Aug 202436.85%3.1610-Q filed, results (8-K)
30 Aug 202432.96%10.38
13 Sep 202433.17%12.25
30 Sep 202436.74%7.55
15 Oct 202439.47%9.45
31 Oct 202438.71%16.80
15 Nov 202437.59%11.6210-Q filed, results (8-K)
29 Nov 202435.67%1.00
13 Dec 202436.62%2.84
31 Dec 202434.57%4.92

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.